[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 40 of about 40
1. Foote RL, Kasperbauer JL, Okuno SH, Nichols DA, Olsen KD, Brown PD, Garces YI, Sargent DJ, Strome SE: A pilot study of high-dose intraarterial cisplatin chemotherapy with concomitant accelerated radiotherapy for patients with previously untreated T4 and selected patients with T3N0-N3M0 squamous cell carcinoma of the upper aerodigestive tract. Cancer; 2005 Feb 1;103(3):559-68
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot study of high-dose intraarterial cisplatin chemotherapy with concomitant accelerated radiotherapy for patients with previously untreated T4 and selected patients with T3N0-N3M0 squamous cell carcinoma of the upper aerodigestive tract.
  • BACKGROUND: This Phase I clinical trial was developed to assess the feasibility of combining high-dose intraarterial cisplatin chemotherapy with concurrent, concomitant boost accelerated radiation therapy for patients with previously untreated T4 and select patients with T3N0-N3M0 squamous cell carcinoma of the upper aerodigestive tract.
  • METHODS: Between July 1999, and February 2002, 19 patients were treated with 3 or 4 weekly cycles of intraarterial Cisplatin chemotherapy (150 mg/m(2)) with concurrent, concomitant boost accelerated radiation therapy (72 grays in 42 fractions over 6 weeks).
  • The fourth patient treated on the modified protocol developed febrile neutropenia, sepsis, and a thromboembolic event, which resulted in lower extremity amputations.
  • With a median follow-up of 21 months (range, 6.2-34.6 months), the overall survival at 1 year was 89.5% (95% confidence interval [95%CI], 76.7-100%).
  • CONCLUSIONS: The results of this study suggest that concurrent intraarterial cisplatin chemotherapy at a dose of 150 mg/m(2) with concomitant boost accelerated radiation therapy is not feasible.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / administration & dosage. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Infusions, Intra-Arterial
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Dose Fractionation. Drug Administration Schedule. Feasibility Studies. Female. Humans. Male. Middle Aged. Neoplasm Staging. Pilot Projects. Prospective Studies. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 American Cancer Society
  • [CommentIn] Cancer. 2005 Feb 1;103(3):447-50 [15633205.001]
  • (PMID = 15597408.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-15083
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


2. Papadimitrakopoulou VA, Hong WK: Biomolecular markers as intermediate end points in chemoprevention trials of upper aerodigestive tract cancer. Int J Cancer; 2000 Dec 15;88(6):852-5
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biomolecular markers as intermediate end points in chemoprevention trials of upper aerodigestive tract cancer.
  • Patients with early-stage disease are often cured with surgery or radiotherapy but are at high risk for second primary tumor (SPT) development (Lippman and Hong, [1989]), and the majority of patients present with advanced disease, for which the outcomes have not markedly improved despite advances in combined-modality therapy (Vokes et al., [1993]).
  • HNSCC arises from transformation of the genetic material of normal cells, followed by successive genetic alterations in a multistep fashion, leading to clonal evolution of progeny cells with a proliferative advantage (Vogelstein and Kinzler, [1993]), induced by tobacco carcinogens (Slaughter et al., [1953]).
  • Chemoprevention studies in upper aerodigestive tract (UADT) cancers are based on these fundamental premises and the identification of molecular genetic and biologic cellular changes.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Carcinoma, Squamous Cell / genetics. Head and Neck Neoplasms / genetics. Retinoids / therapeutic use
  • [MeSH-minor] Clinical Trials as Topic. DNA Methylation. Drug Resistance, Neoplasm. Gene Silencing. Genes, p16 / genetics. Genes, p53 / genetics. Genetic Markers. Humans. Loss of Heterozygosity. Receptor, Epidermal Growth Factor / metabolism. Receptors, Retinoic Acid / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11093804.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Genetic Markers; 0 / Receptors, Retinoic Acid; 0 / Retinoids; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


3. Kim TM, Heo DS: Extranodal NK / T-cell lymphoma, nasal type: new staging system and treatment strategies. Cancer Sci; 2009 Dec;100(12):2242-8
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal NK / T-cell lymphoma, nasal type: new staging system and treatment strategies.
  • NTCL subsets are classified as upper aerodigestive tract (UAT) NTCL or non-UAT NTCL; non-UAT has pathologic similarity to UAT-NTCL but is a clinically distinct subtype.
  • Due to the clinical heterogeneity of NTCL, optimal treatment modalities and prognostic factors have been difficult to determine.
  • Thus, a new staging system is proposed: limited disease (stage I/II UAT-NTCL without local tumor invasiveness) and extensive disease (stage I/II with local invasiveness or stage III/IV disease of UAT NTCL, and non-UAT NTCL) based on treatment outcomes.
  • NTCL is resistant to anthracycline-based chemotherapy, whereas non-anthracycline combination chemotherapy (such as ifosfamide, methotrexate, etoposide, and prednisolone) has an activity against NTCL as either a front-line or as a second-line treatment.
  • [MeSH-major] Lymphoma, Extranodal NK-T-Cell / pathology. Nose Neoplasms / pathology
  • [MeSH-minor] Humans. Neoplasm Staging. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19758393.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 65
  •  go-up   go-down


Advertisement
4. Grandis JR, Pietenpol JA, Greenberger JS, Pelroy RA, Mohla S: Head and neck cancer: meeting summary and research opportunities. Cancer Res; 2004 Nov 1;64(21):8126-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Head and neck squamous cell carcinoma (HNSCC) is the most common malignant neoplasm arising in the mucosa of the upper aerodigestive tract.
  • Currently used therapeutic modalities (surgery, radiation, and/or chemotherapy) have been associated with rather modest improvements in patient survival.
  • The Head and Neck Cancer: Research and Therapeutic Opportunities Workshop (held in Washington, DC, May 24-26, 2004) was organized by the Division of Cancer Biology at the National Cancer Institute to identify research areas and directions that will advance understanding of HNSCC biology and accelerate clinical translation.
  • The overall consensus was that HNSCC is a relatively understudied malignancy and that investigations that focus on the biology of this tumor have the potential to impact significantly on the prevention and treatment of epithelial malignancies.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / therapy


5. Julieron M, Temam S: [Locoregional recurrence of ORL cancer: the place of surgery]. Bull Cancer; 2004 Nov;91(11):863-9
MedlinePlus Health Information. consumer health - Throat Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Récidives locorégionales des cancers ORL: place de la chirurgie.
  • Due to progress of radiotherapy, especially modification of fractionation and association with chemotherapy, the problem of salvage surgery is nowadays emphasized.
  • The poor postoperative, functional and oncologic results after salvage surgery, especially in pharyngeal tumors must be taken into account for the decision of primary treatment.
  • Regarding the important locoregional aggressivity of squamous cell carcinomas of the upper aerodigestive tract, these results must be kept in mind when preservation protocols are in question.
  • [MeSH-major] Laryngeal Neoplasms / surgery. Mouth Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Pharyngeal Neoplasms / surgery. Salvage Therapy / methods
  • [MeSH-minor] Humans. Hypopharyngeal Neoplasms / radiotherapy. Hypopharyngeal Neoplasms / surgery. Oropharyngeal Neoplasms / radiotherapy. Oropharyngeal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15582890.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 44
  •  go-up   go-down


6. Jiménez C, Manrique A, Marqués E, Ortega P, Loinaz C, Gómez R, Meneu JC, Abradelo M, Moreno A, López A, Moreno E: Incidence and risk factors for the development of lung tumors after liver transplantation. Transpl Int; 2007 Jan;20(1):57-63
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tobacco and immunosuppression are risk factors for developing upper aerodigestive and lung tumors after transplantation.
  • Mean time from OLT to tumor diagnosis was 86 months.
  • Tumor resection was performed in one patient, and three also received chemotherapy.
  • [MeSH-major] Liver Transplantation / adverse effects. Lung Neoplasms / epidemiology. Postoperative Complications / epidemiology
  • [MeSH-minor] Adolescent. Adult. Alcohol Drinking / adverse effects. Humans. Immunosuppression / adverse effects. Incidence. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Factors. Smoking / adverse effects. Spain / epidemiology. Survival Analysis. Survivors

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Transpl Int. 2007 Feb;20(2):201. Ortegz, Patricia [corrected to Ortega, Patricia]
  • (PMID = 17181654.001).
  • [ISSN] 0934-0874
  • [Journal-full-title] Transplant international : official journal of the European Society for Organ Transplantation
  • [ISO-abbreviation] Transpl. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


7. Basu D, Nguyen TT, Montone KT, Zhang G, Wang LP, Diehl JA, Rustgi AK, Lee JT, Weinstein GS, Herlyn M: Evidence for mesenchymal-like sub-populations within squamous cell carcinomas possessing chemoresistance and phenotypic plasticity. Oncogene; 2010 Jul 22;29(29):4170-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Variable drug responses among malignant cells within individual tumors may represent a barrier to their eradication using chemotherapy.
  • Carcinoma cells expressing mesenchymal markers resist conventional and epidermal growth factor receptor (EGFR)-targeted chemotherapy.
  • In this study, we evaluated whether mesenchymal-like sub-populations within human squamous cell carcinomas (SCCs) with predominantly epithelial features contribute to overall therapy resistance.
  • We identified a mesenchymal-like subset expressing low E-cadherin (Ecad-lo) and high vimentin within the upper aerodigestive tract SCCs.

  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9455-62 [16230409.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8686-98 [16361555.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1136-44 [16731745.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2666-72 [16763281.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):4103-11 [16818711.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4147-53 [16857785.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4170-6 [16943533.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8319-26 [16951136.001]
  • [Cites] Mol Cancer Ther. 2007 Jan;6(1):277-85 [17237287.001]
  • [Cites] Nat Rev Cancer. 2007 Jun;7(6):415-28 [17508028.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2164-70 [17538160.001]
  • [Cites] Mol Cancer Ther. 2007 Jun;6(6):1683-91 [17541031.001]
  • [Cites] Br J Cancer. 2007 Aug 20;97(4):494-501 [17622245.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):76-83 [10655586.001]
  • [Cites] J Biol Chem. 2000 Oct 6;275(40):30934-42 [10908564.001]
  • [Cites] Cancer Res. 1981 May;41(5):1657-63 [7214336.001]
  • [Cites] J Biol Chem. 1998 Sep 11;273(37):23912-21 [9727005.001]
  • [Cites] Am J Pathol. 2005 May;166(5):1541-54 [15855653.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):5996-6000; discussion 6000-1 [16024596.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5578-87 [16009949.001]
  • [Cites] Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S159-71 [16113092.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9328-37 [16230395.001]
  • [Cites] J Cell Physiol. 2007 Nov;213(2):374-83 [17680632.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1695-704 [17960012.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1705-15 [17960013.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2391-9 [18381447.001]
  • [Cites] Cancer. 2008 May 1;112(9):2088-100 [18327819.001]
  • [Cites] Nat Cell Biol. 2008 May;10(5):593-601 [18376396.001]
  • [Cites] Cell. 2008 May 16;133(4):704-15 [18485877.001]
  • [Cites] Bioinformatics. 2008 Jul 1;24(13):1547-8 [18467348.001]
  • [Cites] Cancer Cell. 2008 Jul 8;14(1):79-89 [18598946.001]
  • [Cites] Curr Protoc Cytom. 2008 Oct;Chapter 9:Unit 9.26 [18972368.001]
  • [Cites] Clin Cancer Res. 2009 Jan 15;15(2):532-42 [19147758.001]
  • [Cites] Cancer Res. 2009 Mar 15;69(6):2400-7 [19276344.001]
  • [Cites] Clin Cancer Res. 2009 Apr 15;15(8):2657-65 [19336515.001]
  • [Cites] Cancer Res. 2009 May 15;69(10):4260-9 [19417139.001]
  • [Cites] Cancer Res. 2009 Jun 15;69(12):5115-25 [19491256.001]
  • [Cites] Crit Rev Immunol. 2009;29(3):241-54 [19538137.001]
  • [Cites] Head Neck. 2009 Aug;31(8):1086-94 [19378324.001]
  • [Cites] Cancer Res. 2009 Aug 15;69(16):6704-12 [19654291.001]
  • [Cites] Clin Cancer Res. 2009 Aug 15;15(16):5060-72 [19671845.001]
  • [Cites] Oncogene. 2009 Aug;28 Suppl 1:S24-31 [19680293.001]
  • [Cites] Cell. 2009 Sep 4;138(5):822-9 [19737509.001]
  • [Cites] Stem Cells. 2009 Sep;27(9):2059-68 [19544473.001]
  • [Cites] Oncogene. 2009 Oct 29;28(43):3801-13 [19684613.001]
  • (PMID = 20498638.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA098101-06A18722; United States / NCI NIH HHS / CA / P01 CA098101; United States / NCI NIH HHS / CA / P30 CA10815; United States / NCI NIH HHS / CA / P30 CA016520; United States / NCI NIH HHS / CA / P01 CA098101-06A18722
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; P88XT4IS4D / Paclitaxel; PQX0D8J21J / Cetuximab
  • [Other-IDs] NLM/ NIHMS196788; NLM/ PMC3039880
  •  go-up   go-down


8. Védrine L, Chargari C, Le Moulec S, Fayolle M, Ceccaldi B, Bauduceau O: [Cancer chemotherapy of the upper aerodigestive tract]. Cancer Radiother; 2008 Mar;12(2):110-9
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cancer chemotherapy of the upper aerodigestive tract].
  • [Transliterated title] Chimiothérapie des cancers des voies aérodigestives supérieures.
  • Tumours of the upper aerodigestive tract represent the sixth most frequent kind of cancer in France and throughout the world.
  • If the localised forms may be controlled in the long run in two thirds of cases by surgery or radiotherapy, only one third of locally advanced forms are accessible to a cure after association from radiotherapy and chemotherapy.
  • Besides, with a median of survival less than six months, metastatic tumours present a catastrophic spontaneous prognosis among patients with a medical ground that is often heavily deteriorated by prolonged exposure to alcohol and tobacco.
  • Thus, there is a necessity to implement adapted therapeutic strategies to each patient and based on satisfactory proof levels of effectiveness.
  • Optimisation of existing chemotherapy protocols and development of new therapies, in particular of targeted therapies, remain an important objective in the hope to improve results of treatments in locally advanced and metastatic cancers of the oral cavity.
  • [MeSH-major] Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Combined Modality Therapy. Humans. Laryngeal Neoplasms / drug therapy. Neoplasm Metastasis. Neoplasm Recurrence, Local / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18187355.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 47
  •  go-up   go-down


9. Ma X, Guo Y, Pang Z, Wang B, Lu H, Gu YJ, Guo X: A randomized phase II study of CEOP with or without semustine as induction chemotherapy in patients with stage IE/IIE extranodal NK/T-cell lymphoma, nasal type in the upper aerodigestive tract. Radiother Oncol; 2009 Dec;93(3):492-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase II study of CEOP with or without semustine as induction chemotherapy in patients with stage IE/IIE extranodal NK/T-cell lymphoma, nasal type in the upper aerodigestive tract.
  • PURPOSE: In this randomized phase II study, we evaluated the efficacy of semustine added to CEOP regimen as induction chemotherapy in patients with stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type in the upper aerodigestive tract.
  • RESULTS: The overall response rate of induction chemotherapy was 57.9% in CEOP arm compared with 62.2% in CEOP plus semustine arm (P=0.71).
  • With a median follow-up of 30.1 months, 2-year overall survival was 73.3% and 62.2%, respectively (P=0.37).
  • More effective treatment needs to be explored in patients with intermediate or high risk.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Extranodal NK-T-Cell / drug therapy. Nose Neoplasms / drug therapy. Semustine / administration & dosage
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Epirubicin / administration & dosage. Epirubicin / adverse effects. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Pharyngeal Neoplasms / drug therapy. Pharyngeal Neoplasms / radiotherapy. Prednisone / administration & dosage. Prednisone / adverse effects. Prognosis. Radiation Injuries. Survival Rate. Vincristine / administration & dosage. Vincristine / adverse effects. Young Adult

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. Semustine .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19782419.001).
  • [ISSN] 1879-0887
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
  • [Publication-country] Ireland
  • [Chemical-registry-number] 13909-09-6 / Semustine; 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CEOP protocol 1
  •  go-up   go-down


10. Laccourreye O, Veivers D, Hans S, Ménard M, Brasnu D, Laccourreye H: Chemotherapy alone with curative intent in patients with invasive squamous cell carcinoma of the pharyngolarynx classified as T1-T4N0M0 complete clinical responders. Cancer; 2001 Sep 15;92(6):1504-11
Hazardous Substances Data Bank. PLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy alone with curative intent in patients with invasive squamous cell carcinoma of the pharyngolarynx classified as T1-T4N0M0 complete clinical responders.
  • BACKGROUND: The current studies documented the results achieved with chemotherapy alone with curative intent in a series of 67 patients with invasive squamous cell carcinoma of the pharyngolarynx classified as T1-T4N0M0 complete clinical responders after a platin-based induction chemotherapy regimen.
  • Local control rates after salvage treatment were 100% in Group I patients and 83% in Group II patients.
  • Laryngeal preservation rates after salvage treatment were 100% in Group I patients and 64% in Group II patients.
  • CONCLUSIONS: The current report 1) contradicts the old dogma of nonchemocurability for invasive squamous cell carcinoma of the upper aerodigestive tract and 2) suggests that the use of a platin-based chemotherapy-alone regimen with curative intent in patients with invasive squamous cell carcinoma of the pharyngolarynx who are classified as T1-T4N0M0 complete clinical responders after receiving an induction chemotherapy regimen is best indicated when the tumor originates from the glottis.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Laryngeal Neoplasms / drug therapy. Pharyngeal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Drug Therapy, Combination. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasms, Second Primary. Platinum / administration & dosage. Salvage Therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11745228.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 49DFR088MY / Platinum; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Saba NF, Khuri FR: Optimizing systemic therapy in squamous cell carcinoma of the head and neck with a focus on targeted agents. Curr Opin Oncol; 2009 May;21(3):232-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimizing systemic therapy in squamous cell carcinoma of the head and neck with a focus on targeted agents.
  • PURPOSE OF REVIEW: Squamous cell carcinoma of head and neck (SCCHN) is the most common neoplasm in the upper aerodigestive tract.
  • In this review, we attempt to summarize the major advances of the last few years with a focus on the use of systemic therapy alone for recurrent or metastatic disease, or in combination with radiation and surgery for locally advanced disease.
  • In 2000, a large meta-analysis concluded that the addition of systemic therapy to radiotherapy was superior to radiotherapy alone in improving outcome for patients with SCCHN.
  • Since then, several clinical trials have established concurrent chemotherapy and radiation as the new standard of care in treatment of locally advanced disease.
  • RECENT FINDINGS: Over the last two decades, new concepts have emerged introducing the novel sequencing of systemic and radiation therapy such as the use of induction chemotherapy and sequential chemotherapy and radiation therapy.
  • Novel targeted agents, including the epidermal growth factor receptor antibody cetuximab, have been approved for use as single agents or in combination with radiation therapy or chemotherapy in treatment of recurrent metastatic disease.
  • SUMMARY: This review aims to condense the most recent advances in SCCHN treatment, focusing on the practice-changing outcomes of pivotal studies namely the use of novel targeted agents.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / therapy. Receptor, Epidermal Growth Factor / drug effects
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cetuximab. Combined Modality Therapy. Disease Progression. Humans. Recurrence

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19370807.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA058187
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab
  • [Number-of-references] 45
  •  go-up   go-down


12. Chen SW, Chang ST, Lu CL, Hwang WS, Tsao CJ, Huang WT, Chang KY, Chuang SS: Upper aerodigestive tract lymphoma in Taiwan. J Clin Pathol; 2010 Oct;63(10):888-93
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upper aerodigestive tract lymphoma in Taiwan.
  • AIM: To better understand the spectrum of primary lymphomas in the upper aerodigestive tract, a common site of extranodal lymphoma.
  • Most patients received chemotherapy with or without radiotherapy.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Child. Epidemiologic Methods. Epstein-Barr Virus Infections / complications. Female. Humans. L-Lactate Dehydrogenase / blood. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / therapy. Lymphoma, B-Cell / virology. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / therapy. Lymphoma, T-Cell / virology. Male. Middle Aged. Mouth Neoplasms / pathology. Mouth Neoplasms / therapy. Mouth Neoplasms / virology. Neoplasm Staging. Prognosis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20876320.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


13. Sanfilippo NJ, Hsi A, DeNittis AS, Ginsberg GG, Kochman ML, Friedberg JS, Hahn SM: Toxicity of photodynamic therapy after combined external beam radiotherapy and intraluminal brachytherapy for carcinoma of the upper aerodigestive tract. Lasers Surg Med; 2001;28(3):278-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxicity of photodynamic therapy after combined external beam radiotherapy and intraluminal brachytherapy for carcinoma of the upper aerodigestive tract.
  • BACKGROUND AND OBJECTIVE: To describe the toxicity of photodynamic therapy (PDT) in patients with carcinoma of the upper aerodigestive tract who received prior treatment with external beam irradiation and intraluminal brachytherapy (IB).
  • Three patients who received prior treatment with external beam irradiation and IB were identified.
  • Two patients had esophageal carcinoma treated with combined chemotherapy and external beam irradiation (55.8 and 50.4 Gy) followed by IB (12 Gy and 35 Gy at 1 cm).
  • These patients then received PDT for treatment of recurrence (2 mg/kg Photofrin injection and 2 light applications: 630 nm, 150--200 J/cm, 200--400 mW/cm).
  • One patient had non-small cell lung cancer treated with external beam irradiation (60 Gy) followed by IB (36.1 Gy at 1 cm) and then received PDT for recurrence (1 mg/kg Photofrin injection and one light application: 630 nm, 150 J/cm, 200 mW/cm).
  • The other esophageal cancer patient developed quadriplegia due to an epidural abscess arising from a fistula with the diseased portion of the esophagus.
  • The lung cancer patient had massive hemoptysis after the procedure and died 2 days later.
  • CONCLUSION: Patients with upper aerodigestive tract carcinoma who have received treatment with both external beam irradiation and IB seem to be at higher risk for complications when treated with PDT.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Esophageal Neoplasms / therapy. Lung Neoplasms / therapy. Neoplasm Recurrence, Local / drug therapy. Photochemotherapy / adverse effects
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brachytherapy. Combined Modality Therapy. Fatal Outcome. Female. Humans. Male. Middle Aged. Prognosis. Radiation Dosage. Risk Assessment

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11295765.001).
  • [ISSN] 0196-8092
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Kagohashi K, Satoh H, Kurishima K, Ishikawa H, Ohtsuka M, Sekizawa K: Lung cancer patients with previous or simultaneous the upper aerodigestive cancers. Tuberk Toraks; 2009;57(2):192-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung cancer patients with previous or simultaneous the upper aerodigestive cancers.
  • There have been few reports on clinical characteristics of lung cancer patients with previous or simultaneous upper aerodigestive cancers.
  • Twenty-one (1.7%) of 1242 patients had previous or simultaneous upper aerodigestive cancers.
  • For non-small cell lung cancer (NSCLC), 6 patients underwent surgical resection and 3 were treated with chemotherapy.
  • Three small cell lung cancer (SCLC) patients had chemotherapy.
  • For patients with upper aerodigestive cancers, smoking cessation, a chest radiograph or computed tomography scan at least yearly and swift evaluation of signs or symptoms that are suggestive of lung cancer should be recommended.
  • [MeSH-major] Lung Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Neoplasms, Second Primary / pathology. Respiratory Tract Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Non-Small-Cell Lung / epidemiology. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Small Cell Lung Carcinoma / epidemiology. Small Cell Lung Carcinoma / pathology. Small Cell Lung Carcinoma / therapy. Smoking / adverse effects. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19714511.001).
  • [ISSN] 0494-1373
  • [Journal-full-title] Tüberküloz ve toraks
  • [ISO-abbreviation] Tuberk Toraks
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


15. Samant S, Robbins KT, Kumar P, Ma JZ, Vieira F, Hanchett C: Bone or cartilage invasion by advanced head and neck cancer: intra-arterial supradose cisplatin chemotherapy and concomitant radiotherapy for organ preservation. Arch Otolaryngol Head Neck Surg; 2001 Dec;127(12):1451-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone or cartilage invasion by advanced head and neck cancer: intra-arterial supradose cisplatin chemotherapy and concomitant radiotherapy for organ preservation.
  • BACKGROUND: Invasion of bony or cartilaginous structures by advanced upper aerodigestive tract cancer has been considered an indication for surgery on the basis of historic experience of poor responsiveness to radiation therapy.
  • At University of Tennessee-Memphis, patients with advanced head and neck cancer have been treated on a protocol of concomitant intra-arterial (targeted) cisplatin and conventional radiation therapy.
  • METHODS: Treatment consisted of 4 weekly intra-arterial infusions of cisplatin (150 mg/m(2) per week), with simultaneous systemic neutralization by intravenous sodium thiosulfate (9 mg/m(2)), and concurrent radiation therapy at 180 rad (1.8 Gy) or 200 rad (2 Gy) per fraction to a planned total of 6600 to 7400 rad (66-74 Gy) to the primary site or overt nodal disease.
  • Presence of bone or cartilage invasion was established by review of tumor diagrams of clinical findings and computed tomography or magnetic resonance imaging reports.
  • CONCLUSION: Equivalent efficacy of treatment in the 2 groups suggests that targeted chemoradiation can be a definitive therapeutic option in patients with advanced head and neck cancer invading bony or cartilaginous structures.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Head and Neck Neoplasms / therapy. Laryngeal Cartilages / pathology. Laryngeal Neoplasms / pathology. Skull Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Neoplasm Invasiveness. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11735813.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA67789
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


16. Ahmed KA, Robbins KT, Wong F, Salazar JE: Efficacy of concomitant chemoradiation and surgical salvage for N3 nodal disease associated with upper aerodigestive tract carcinoma. Laryngoscope; 2000 Nov;110(11):1789-93
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of concomitant chemoradiation and surgical salvage for N3 nodal disease associated with upper aerodigestive tract carcinoma.
  • OBJECTIVES/HYPOTHESIS: To determine whether an aggressive approach using trimodality therapy would improve the outcome in head and neck cancer patients with advanced (N3) nodal disease.
  • STUDY DESIGN: In this retrospective, nonrandomized review, we analyzed a subset of patients who were treated in a targeted chemoradiation therapy protocol, consisting of 31 patients who received treatment between June 1993 and June 1997.
  • METHODS: Patients received selective intra-arterial infusions of cisplatin (150 mg/m2/wk for 4 weeks) and concomitant radiation therapy (2 Gy/fraction x 35 daily fractions over a 7-wk period) to the primary and clinically positive nodal disease.
  • With a median follow-up of 15 months (range, 4-41 mo), the 3-year overall survival and disease-specific survival were 41% and 43%, respectively.
  • CONCLUSIONS: Targeted chemoradiation therapy followed by surgical salvage is a highly effective approach for regional control of patients with N3 nodal disease, whereas additional strategies are required to address the problem of distant metastases.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Drug Administration Schedule. Female. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Neoplasm Staging. Radiation-Sensitizing Agents / therapeutic use. Retrospective Studies. Salvage Therapy. Survival Analysis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11081585.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiation-Sensitizing Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


17. Pfreundner L, Willner J, Marx A, Hoppe F, Beckmann G, Flentje M: The influence of the radicality of resection and dose of postoperative radiation therapy on local control and survival in carcinomas of the upper aerodigestive tract. Int J Radiat Oncol Biol Phys; 2000 Jul 15;47(5):1287-97
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of the radicality of resection and dose of postoperative radiation therapy on local control and survival in carcinomas of the upper aerodigestive tract.
  • PURPOSE: To evaluate dose concepts in postoperative irradiation of carcinomas of the upper aerodigestive tract according to the radicality of resection.
  • PATIENTS AND METHODS: In a retrospective analysis, the charts of 257 patients with histologically-proven carcinoma of the upper aerodigestive tract (40 T1, 80 T2, 53 T3, 84 T4 tumors, with nodal involvement in 181 cases) were reviewed according to the radicality of resection and dose of irradiation administered.
  • A median dose of 56 Gy was applied to the primary tumor bed and the cervical lymphatics (2 Gy/fraction, 5 fractions/week).
  • In cases of R1 or R2 resection, or of close margins (< 3 mm), the tumor bed or, respectively, tumor residuals were boosted with doses up to a median of 66 Gy.
  • Patients with R1 and R2 resections should be treated with doses of more than 68 Gy (2 Gy/fraction, 5 fractions/week) (with close margins [< 3 mm] more than 66 Gy) to achieve an improvement in locoregional control and survival.
  • [MeSH-major] Carcinoma / radiotherapy. Carcinoma / surgery. Pharyngeal Neoplasms / radiotherapy. Pharyngeal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy. Hypopharyngeal Neoplasms / surgery. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local / pathology. Neoplasm, Residual. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / radiotherapy. Oropharyngeal Neoplasms / surgery. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10889383.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 39
  •  go-up   go-down


18. Burian M: [Recommendation for guidelines in the treatment of squamous cell cancer of the upper aerodigestive tract]. Wien Med Wochenschr; 2008;158(9-10):283-93

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recommendation for guidelines in the treatment of squamous cell cancer of the upper aerodigestive tract].
  • [Transliterated title] Ein Vorschlag für Leitlinien der Behandlung von Plattenepithelkarzinomen des oberen Aerodigestivtraktes.
  • If we look at the historical development of the treatment of head and neck cancer, we can see that initially, decisions about therapy lay solely in the hands of the surgeons (Otorhinolaryngologists, oral and maxilla-facial surgeons) This was also true of the decision as to whether an operation was feasible or whether primary radio therapy was to be carried out.
  • At the end of the last century, after chemotherapy had become an integral part of curative therapy, inter-disciplinary conferences (tumour boards) were set up so that the surgeons could make joint decisions about therapy together with radio oncologists and medical oncologists.
  • In addition, the increasingly important role of chemotherapy in curative therapy in the last fifteen years has led to a marked increase in the number of clinical studies in head and neck cancer.
  • Inter-disciplinary treatment decisions can be based only on current scientific knowledge and are geared towards a standard treatment as recommended for an individual tumour stage.
  • It is precisely in the upper aerodigestive tract that there are various therapeutical procedures, due to the different site of primaries (oral cavity, oro-, hypoparynx and larynx) and the different grade of locoregional metastasis.
  • One possible way to assure a high degree of transparency of these various therapies and making them available to a high number of colleagues is the development guidelines [1].
  • Many medical associations and organisations in Austria are currently engaged in the formulation and definition of guidelines, in order to provide the highest possible quality of medical treatment and care for each individual patient.
  • By guidelines are meant recommendations for treatments which allow a certain amount of flexibility in the treatment and provide a medical consensus in line with current scientific knowledge.
  • The following proposal is designed to provide a basis for the formulation of guidelines for the treatment of head and neck cancer in Austria.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Otorhinolaryngologic Neoplasms / therapy. Practice Guidelines as Topic
  • [MeSH-minor] Algorithms. Austria. Cooperative Behavior. Humans. Neoplasm Staging. Patient Care Team

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18560956.001).
  • [ISSN] 0043-5341
  • [Journal-full-title] Wiener medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Wien Med Wochenschr
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


19. Prasad ML, Busam KJ, Patel SG, Hoshaw-Woodard S, Shah JP, Huvos AG: Clinicopathologic differences in malignant melanoma arising in oral squamous and sinonasal respiratory mucosa of the upper aerodigestive tract. Arch Pathol Lab Med; 2003 Aug;127(8):997-1002
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic differences in malignant melanoma arising in oral squamous and sinonasal respiratory mucosa of the upper aerodigestive tract.
  • Sinonasal melanoma showed vascular and deep tissue invasion more frequently than oral melanoma; however, no significant difference in disease-specific survival was noted (median survival, 2.8 years vs 3.0 years; 5-year survival, 37% vs 35%, respectively).
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Head and Neck Neoplasms / pathology. Maxillary Sinus Neoplasms / pathology. Melanoma / pathology. Mouth Mucosa / pathology. Mouth Neoplasms / pathology. Nose Neoplasms / pathology. Respiratory Mucosa / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Nasal Mucosa / drug effects. Nasal Mucosa / pathology. Nasal Mucosa / surgery. Neoplasm Invasiveness / pathology. Paranasal Sinus Neoplasms / drug therapy. Paranasal Sinus Neoplasms / mortality. Paranasal Sinus Neoplasms / pathology. Paranasal Sinus Neoplasms / surgery


20. Arnold DJ, Goodwin WJ, Weed DT, Civantos FJ: Treatment of recurrent and advanced stage squamous cell carcinoma of the head and neck. Semin Radiat Oncol; 2004 Apr;14(2):190-5
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of recurrent and advanced stage squamous cell carcinoma of the head and neck.
  • Despite advances in our ability to safely treat patients with recurrent cancer of the upper aerodigestive tract, outcomes for retreatment are generally poor and the first chance to cure these patients remains the best chance.
  • Thorough knowledge of the outlook and options for patients with recurrent disease is also of significance in choosing therapy for patients with newly diagnosed disease.
  • This is especially true for newly diagnosed patients making the choice between surgery and nonsurgical ("organ-sparing") options, who need to know the outlook for salvage surgery, should they recur after radiation with or without concomitant chemotherapy.
  • Unfortunately, the results of surgical salvage are generally poor for patients with advanced stage recurrence and for those who recur after treatment of advanced disease.
  • Patients choosing nonsurgical treatment for newly diagnosed cancer of the pharynx cannot rely on salvage surgery in the event of recurrence.
  • Reirraditation for patients who have failed initial treatment that included radiation therapy has been used at a number of institutions with some success.
  • Experience using reirradiation with or without concomitant chemotherapy continues to evolve.
  • Palliative chemotherapy is an option for most patients, but response rates are generally poor and of short duration, after failure of initial treatment that includes radiation therapy.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Humans. Retreatment / methods. Salvage Therapy / methods

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15095264.001).
  • [ISSN] 1053-4296
  • [Journal-full-title] Seminars in radiation oncology
  • [ISO-abbreviation] Semin Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


21. Mukherji SK, Weadock WJ: Imaging of the post-treatment larynx. Eur J Radiol; 2002 Nov;44(2):108-19

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging of the post-treatment larynx.
  • The treatment for squamous cell carcinoma of the upper aerodigestive tract includes surgery, radiation therapy (RT), chemotherapy or a combination of various modalities.
  • Familiarization with the expected imaging changes following therapy allow accurate evaluation of imaging studies and may prevent misinterpretation of post-treatment changes as recurrent disease.
  • The intent of this manuscript will be to review the post-treatment appearance of the larynx following RT and various types of laryngectomy.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Laryngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / surgery. Larynx / radiography. Neoplasm Recurrence, Local / radiography
  • [MeSH-minor] Combined Modality Therapy. Diagnosis, Differential. Humans. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12413679.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 17
  •  go-up   go-down


22. Bauman JE, Eaton KD, Martins RG: Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. Arch Dermatol; 2007 Jul;143(7):889-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of recurrent squamous cell carcinoma of the skin with cetuximab.
  • BACKGROUND: Squamous cell carcinoma of the skin (SCCS) is rarely encountered by medical oncologists owing to success of local therapies.
  • When advanced SCCS requires systemic palliation, treatment with conventional chemotherapy, such as cisplatin, is often precluded by a patient's age or medical comorbidities.
  • This drug, approved for treatment of squamous cell carcinoma of the upper aerodigestive tract as well as colorectal cancer, is well tolerated.
  • The drug was well tolerated, with the exception of acneiform rash requiring dose reduction in 1 patient.
  • Both patients had excellent responses to cetuximab: the first patient had complete response by week 16 of treatment and the second a near-complete response by week 12.
  • In both cases, initial response to cetuximab was evident by week 4 of therapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Epidermal Growth Factor. Neoplasm Recurrence, Local / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Humanized. Cetuximab. Combined Modality Therapy. Face / pathology. Female. Humans. Male. Nose / pathology. Scalp / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638733.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 62229-50-9 / Epidermal Growth Factor; PQX0D8J21J / Cetuximab
  •  go-up   go-down


23. Allegretti JP, Panje WR: Electroporation therapy for head and neck cancer including carotid artery involvement. Laryngoscope; 2001 Jan;111(1):52-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Electroporation therapy for head and neck cancer including carotid artery involvement.
  • OBJECTIVES: Electroporation therapy with intralesional bleomycin (EPT) is a novel, technically simple outpatient technique in which high-voltage electric impulses delivered into a neoplasm transiently increase cell membrane permeability to large molecules, including cytotoxic agents, causing localized progressive necrosis.
  • Additionally, we have used this approach to treat four additional patients (total: 9 males/5 females) with upper aerodigestive tract squamous cell carcinoma, including three with internal carotid artery (ICA) involvement up to or within the skull base.
  • Both patients with ICA involvement had a partial or complete response to treatment; neither patient had a hemorrhagic or neurologic complication.
  • There were no treatment-related deaths.
  • Patients with early stage recurrences have the potential for prolonged survival beyond 2 years without the morbidity of surgery and radiation or toxicity of systemic chemotherapy.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Antimetabolites, Antineoplastic / therapeutic use. Bleomycin / therapeutic use. Carotid Artery Diseases / drug therapy. Electroporation. Head and Neck Neoplasms / drug therapy. Vascular Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ambulatory Care. Carcinoma, Squamous Cell / drug therapy. Carotid Arteries. Carotid Artery, Internal / drug effects. Cell Membrane Permeability / drug effects. Cerebrovascular Circulation / physiology. Cohort Studies. Embolization, Therapeutic. Female. Follow-Up Studies. Humans. Injections, Intralesional. Male. Middle Aged. Necrosis. Neoplasm Recurrence, Local / drug therapy. Neoplasm Staging. Prospective Studies. Remission Induction. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Carotid Artery Disease.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11192900.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 11056-06-7 / Bleomycin
  •  go-up   go-down


24. Ananth S, Amin M: Implantation of oral squamous cell carcinoma at the site of a percutaneous endoscopic gastrostomy: a case report. Br J Oral Maxillofac Surg; 2002 Apr;40(2):125-30
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 55-year-old man had an operation and radiotherapy for a squamous cell carcinoma of the oral cavity and developed a metastatic deposit at the site of a percutaneous endoscopic gastrostomy, with no other evidence of systemic spread.
  • Treatment of the metastasis was by neo-adjuvant chemotherapy with cisplatin and 5-fluorouracil (5-FU) followed by en bloc resection of the stomal recurrence on the anterior abdominal wall.
  • Only 17 other cases of metastasis to this site from a primary tumour in the upper aerodigestive tract have been reported.
  • [MeSH-major] Abdominal Neoplasms / etiology. Abdominal Neoplasms / secondary. Carcinoma, Squamous Cell / secondary. Gastrostomy / adverse effects. Head and Neck Neoplasms / pathology. Intubation, Gastrointestinal / adverse effects. Neoplasm Seeding

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12180203.001).
  • [ISSN] 0266-4356
  • [Journal-full-title] The British journal of oral & maxillofacial surgery
  • [ISO-abbreviation] Br J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Scotland
  • [Number-of-references] 29
  •  go-up   go-down


25. Djalilian HR, Caicedo E, Lessan K, Grami V, Le CT, Spellman SR, Pambuccian S, Hall WA, Low WC, Ondrey FG: Efficacy of an osmotic pump delivered, GM-CSF-based tumor vaccine in the treatment of upper aerodigestive squamous cell carcinoma in rats. Cancer Immunol Immunother; 2007 Aug;56(8):1207-14
Hazardous Substances Data Bank. INDOMETHACIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of an osmotic pump delivered, GM-CSF-based tumor vaccine in the treatment of upper aerodigestive squamous cell carcinoma in rats.
  • PURPOSE: Upper aerodigestive tract (UADT) cancer has not experienced significant overall survival improvement for over 20 years, and no successful treatments for systemic disease exist.
  • Most patients with UADT cancer experience immune suppression, therefore immune restorative therapies may offer promise for these patients.
  • We presently tested the efficacy of granulocyte macrophage-colony stimulating factor (GM-CSF) delivered via 28-day continuous infusion pump, in combination with irradiated tumor cells, in a flank model of UADT cancer.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Carcinoma, Squamous Cell / therapy. Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use. Immunotherapy, Active. Infusion Pumps, Implantable. Pharyngeal Neoplasms / pathology
  • [MeSH-minor] Animals. CD4-Positive T-Lymphocytes / pathology. Cell Line, Tumor / radiation effects. Cell Line, Tumor / transplantation. Drug Screening Assays, Antitumor. Drug Synergism. Feasibility Studies. Indomethacin / therapeutic use. Injections, Subcutaneous. Interleukin-12 / therapeutic use. Lymphocytes, Tumor-Infiltrating / pathology. Macrophages / pathology. Mice. Neoplasm Transplantation. Osmosis. Rats. Rats, Inbred F344. Single-Blind Method. Tumor Burden

  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17219150.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cancer Vaccines; 187348-17-0 / Interleukin-12; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; XXE1CET956 / Indomethacin
  •  go-up   go-down


26. Pavlidis N, Pentheroudakis G, Plataniotis G: Cervical lymph node metastases of squamous cell carcinoma from an unknown primary site: a favourable prognosis subset of patients with CUP. Clin Transl Oncol; 2009 Jun;11(6):340-8
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A standardised diagnostic work-up consisting of panendoscopy of the upper aerodigestive tract, CT of the chest/abdomen and histology supplemented by immunohistochemistry is warranted for the diagnosis.
  • The cornerstones of management are excisional biopsy or surgical extirpation of the disease followed by bilateral neck external beam radiotherapy and chemotherapy.
  • The necessity for complete surgical resection of involved neck nodes, irradiation of all head/neck mucosal sites and administration of concurrent chemotherapy is currently being debated.
  • Aggressive multimodal therapy results in longterm disease control in 50-60% of patients, though data are mainly based on retrospective cohorts.
  • Factors predicting for superior patient outcome are radical management with surgery or radiotherapy, low stage and volume of disease, absence of extracapsular spread and good performance status.
  • Recently introduced molecular profiling platforms may provide biological classification to a primary tissue of origin as well as insights into the pathophysiology of this clinical entity.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Lymphatic Metastasis. Neoplasms, Unknown Primary / pathology
  • [MeSH-minor] Alcoholism / epidemiology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor. Clinical Trials as Topic. Combined Modality Therapy. Diagnostic Imaging. Female. Gene Expression Profiling. Humans. Lymph Node Excision. Male. Neck. Neck Dissection. Neoplasm Recurrence, Local. Prognosis. Radiotherapy, Adjuvant / methods. Risk Factors. Smoking / epidemiology. Tonsillectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2003 Sep;39(14):1990-2005 [12957453.001]
  • [Cites] Oncologist. 2007 Apr;12(4):418-25 [17470684.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):55-63 [11316546.001]
  • [Cites] Radiol Clin North Am. 1989 Mar;27(2):331-51 [2645606.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2002 Jul;259(6):325-33 [12115082.001]
  • [Cites] Laryngoscope. 1997 Jun;107(6):759-64 [9185732.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2653-8 [16763279.001]
  • [Cites] Cancer Treat Rev. 2006 Dec;32(8):637-44 [17046164.001]
  • [Cites] Laryngoscope. 2002 Nov;112(11):2009-14 [12439171.001]
  • [Cites] Ned Tijdschr Geneeskd. 2000 Jul 8;144(28):1355-60 [10923158.001]
  • [Cites] Tumori. 1977 May-Jun;63(3):267-82 [898294.001]
  • [Cites] Head Neck. 2002 Apr;24(4):361-9 [11933178.001]
  • [Cites] Cancer. 1989 Jul 15;64(2):510-5 [2736495.001]
  • [Cites] Laryngoscope. 1992 Aug;102(8):884-90 [1495353.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 7;91(7):599-604 [10203278.001]
  • [Cites] Cancer. 2004 Dec 1;101(11):2641-9 [15517576.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 Mar;10 (3):411-23 [6706735.001]
  • [Cites] Head Neck. 2006 Dec;28(12):1090-8 [16933316.001]
  • [Cites] Am J Surg. 1990 Oct;160(4):443-6 [2221252.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1051-8 [17716824.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):727-33 [11395241.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 Mar;124(3):331-3 [11241001.001]
  • [Cites] Nucl Med Commun. 2007 May;28(5):365-71 [17414886.001]
  • [Cites] Head Neck. 1998 Dec;20(8):674-81 [9790287.001]
  • [Cites] Cancer Treat Rev. 2004 Apr;30(2):153-64 [15023433.001]
  • [Cites] Otolaryngol Head Neck Surg. 2008 Sep;139(3):429-35 [18722226.001]
  • [Cites] Head Neck. 1998 Dec;20(8):739-44 [9790297.001]
  • [Cites] Surg Gynecol Obstet. 1957 May;104(5):607-17 [13433258.001]
  • [Cites] Asian J Surg. 2002 Apr;25(2):188-93 [12376245.001]
  • [Cites] Laryngoscope. 1998 Nov;108(11 Pt 1):1605-10 [9818813.001]
  • [Cites] Semin Oncol. 2008 Jun;35(3):274-85 [18544442.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1937-44 [15128893.001]
  • [Cites] Radiology. 1984 Sep;152(3):749-53 [6463256.001]
  • [Cites] Cancer Treat Rev. 2009 May;35(3):221-7 [19046817.001]
  • [Cites] Radiother Oncol. 2001 Jun;59(3):319-21 [11369074.001]
  • [Cites] Eur J Cancer. 2007 Sep;43(14):2026-36 [17698346.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 Jan-Feb;12(1):19-24 [1846994.001]
  • [Cites] Laryngoscope. 2007 Jul;117(7):1173-9 [17603315.001]
  • [Cites] J Nucl Med. 2003 Aug;44(8):1301-14 [12902422.001]
  • [Cites] Head Neck. 2002 Mar;24(3):236-46 [11891955.001]
  • [Cites] Semin Oncol. 1993 Jun;20(3):273-8 [8503023.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(4):743-9 [1618667.001]
  • [Cites] Br J Oral Maxillofac Surg. 2008 Jun;46(4):283-7 [18243447.001]
  • [Cites] Eur Radiol. 2009 Mar;19(3):731-44 [18925401.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):92-8 [12506176.001]
  • [Cites] Cancer. 1973 Apr;31(4):854-9 [4706050.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1945-52 [15128894.001]
  • [Cites] Ann Oncol. 2003 Aug;14(8):1306-11 [12881397.001]
  • [Cites] Head Neck. 2000 Jul;22(4):336-40 [10862015.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] N Engl J Med. 2008 Sep 11;359(11):1116-27 [18784101.001]
  • [Cites] Diagn Cytopathol. 1997 Jul;17(1):70-3 [9218909.001]
  • [Cites] Radiother Oncol. 2000 May;55(2):121-9 [10799723.001]
  • [Cites] Laryngoscope. 1987 Sep;97(9):1080-4 [3626734.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 May;8(5):799-809 [18471051.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Jan;5(1):24-31 [18097454.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):709-20 [10793107.001]
  • [Cites] Ann Oncol. 2000 Jan;11(1):11-6 [10690381.001]
  • (PMID = 19531448.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 58
  •  go-up   go-down


27. Rapoport A, Botelho RA, Souza RP, Cavalcanti SM, Furlam S, Tornin Ode S, Souza TR: The importance of pre-epiglottis space invasion in the treatment planning of larynx and hypopharynx cancer. Braz J Otorhinolaryngol; 2008 Jan-Feb;74(1):74-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The importance of pre-epiglottis space invasion in the treatment planning of larynx and hypopharynx cancer.
  • AIM: The aim of this study was to evaluate inter-observer and intra-observer agreement by means of computed tomography analysis regarding the involvement of the pre-epiglottis space (PES) from carcinoma of the upper aerodigestive tract and its relation with therapeutic planning.
  • MATERIALS AND METHODS: Retrospective study of ninety-five computed tomography exams of patients with squamous cell carcinoma, from 1990 to 2004, were selected and evaluated; 87 were males and eight females, with ages ranging from 32 to 73 years.
  • No patient had received any previous treatment up to the moment of imaging examination, such as surgery, chemotherapy or radiotherapy.
  • CONCLUSIONS: After a general Kappa Index of 0.72, the results suggest a substantial agreement in the involvement of the PES by means of computed tomography analysis.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Epiglottis / pathology. Hypopharyngeal Neoplasms / pathology. Laryngeal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Observer Variation. Reproducibility of Results. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18392505.001).
  • [ISSN] 1808-8694
  • [Journal-full-title] Brazilian journal of otorhinolaryngology
  • [ISO-abbreviation] Braz J Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


28. Kong L, Lu JJ, Hu C, Guo X, Wu Y, Zhang Y: The risk of second primary tumors in patients with nasopharyngeal carcinoma after definitive radiotherapy. Cancer; 2006 Sep 15;107(6):1287-93
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The risk of second primary tumors in patients with nasopharyngeal carcinoma after definitive radiotherapy.
  • The objective of this retrospective analysis was to evaluate such risks in patients with NPC after they received definitive radiation treatment.
  • METHODS: Three hundred twenty-six consecutive patients with pathologically confirmed, nonmetastatic, undifferentiated NPC who received treatment between January 1, 1994 and December 30, 1995 were analyzed.
  • All patients received definitive radiotherapy with either Cobalt-60 or megavoltage therapy.
  • High-dose-rate brachytherapy was given to 23 patients either as part of their primary treatment or as adjuvant treatment for residual lesions.
  • Seventeen patients (5.2%) developed SPTs, for an average annual rate of 1.0%, and the 5-year cumulative incidence was 5.8%.
  • Eleven patients (64.7%) had tumors of the upper aerodigestive tract (UADT).
  • Advanced age (age >or=50 years) was associated with a 37% increased risk of developing SPTs (relative risk, 1.367; 95% confidence interval, 1.067-1.1753; P = .014).
  • Other factors, including gender, tumor or lymph node classification, chemotherapy, total radiation dose to the nasopharynx, reirradiation, and adjuvant brachytherapy did not influence the risk of SPTs.
  • CONCLUSIONS: SPTs in patients with NPC occurred preferentially in the UADT and tended to develop within the irradiated field >5 years after patients received radiation.
  • [MeSH-major] Nasopharyngeal Neoplasms / radiotherapy. Neoplasms, Second Primary / etiology. Radiotherapy / adverse effects
  • [MeSH-minor] Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Retrospective Studies. Risk Factors. Time Factors

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 16909425.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Frank DK, Hu KS, Culliney BE, Persky MS, Nussbaum M, Schantz SP, Malamud SC, Holliday RA, Khorsandi AS, Sessions RB, Harrison LB: Planned neck dissection after concomitant radiochemotherapy for advanced head and neck cancer. Laryngoscope; 2005 Jun;115(6):1015-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES/HYPOTHESIS: Since 1998, at our academic, multidisciplinary head and neck cancer treatment center, it has been our policy to treat appropriate patients with locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN) with concomitant radiochemotherapy followed within 6 weeks by planned neck dissection(s).
  • Our objective was to investigate the oncologic efficacy of planned neck dissection, to date, in this patient population with a focus on outcomes in the neck.
  • For each patient, preradiochemotherapy primary and neck stage, postradiochemotherapy/preneck dissection clinical and radiographic neck status, type of neck dissection(s) performed, pathologic status of the neck dissection specimen(s), length of follow-up (after planned neck dissection), disease status at last follow-up, and site(s) of recurrence were recorded.
  • Thirty-two (82%) patients had N2 or greater neck disease, with 29 (74%) having T3/T4 disease at various upper aerodigestive tract primary sites.
  • Patients received an average of 6,700 cGy and 6,000 cGy external beam radiation therapy to primary disease sites and involved cervical lymphatics respectively, concomitant with one of three platinum-based chemotherapy schedules.
  • At a mean follow-up time of 24 (range 8-57) months for the entire study population, there has been only one neck recurrence (N2A neck).
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / therapy. Neck Dissection / methods
  • [MeSH-minor] Combined Modality Therapy. Follow-Up Studies. Humans. Middle Aged. Neoplasm Recurrence, Local. Neoplasm, Residual. Patient Care Team. Postoperative Complications. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15933512.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Sciubba JJ: Oral cancer. The importance of early diagnosis and treatment. Am J Clin Dermatol; 2001;2(4):239-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral cancer. The importance of early diagnosis and treatment.
  • Proliferative verrucous leukoplakia represents a relatively new type of leukoplakia that is separate from the more common or less innocuous form of this condition.
  • Squamous cell carcinoma will develop from antecedent dysplastic oral mucosal lesions if an early diagnosis has not been made and treatment given.
  • Surgical management of this disease remains the mainstay of treatment.
  • Other therapies include radiation and chemotherapy options that may be used adjunctively and palliatively.
  • Following treatment, it is important to understand the significant risks of second primary cancers developing within the upper aerodigestive tract as a result of field cancerization.
  • The most important message is that early detection of the asymptomatic early stage oral cancer translates in general terms to satisfactory clinical outcome and cure in most patients.
  • [MeSH-major] Mouth Neoplasms. Precancerous Conditions
  • [MeSH-minor] Biopsy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Carcinoma, Squamous Cell / therapy. Carcinoma, Verrucous / diagnosis. Carcinoma, Verrucous / pathology. Carcinoma, Verrucous / surgery. Carcinoma, Verrucous / therapy. Combined Modality Therapy. Diagnosis, Differential. Humans. Leukoplakia, Oral / diagnosis. Leukoplakia, Oral / pathology. Leukoplakia, Oral / surgery. Leukoplakia, Oral / therapy. Neoplasm Staging. Palatal Neoplasms / diagnosis. Palatal Neoplasms / pathology. Palatal Neoplasms / surgery. Palatal Neoplasms / therapy. Palliative Care. Prognosis. Risk Factors. Time Factors. Tongue / pathology. Tongue Neoplasms / diagnosis. Tongue Neoplasms / pathology. Tongue Neoplasms / surgery. Tongue Neoplasms / therapy. World Health Organization

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11705251.001).
  • [ISSN] 1175-0561
  • [Journal-full-title] American journal of clinical dermatology
  • [ISO-abbreviation] Am J Clin Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Number-of-references] 39
  •  go-up   go-down


31. Paulino AF, Singh B, Shah JP, Huvos AG: Basaloid squamous cell carcinoma of the head and neck. Laryngoscope; 2000 Sep;110(9):1479-82
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE/HYPOTHESIS: Basaloid squamous cell carcinoma (BSCC), an uncommon tumor with predilection for the upper aerodigestive tract, is a distinct variant of squamous carcinoma, because of its unique histological features and ominous clinical behavior.
  • Their ages ranged from 43 to 85 years, with a mean age of 62 years.
  • Treatment modalities included surgery with or without chemotherapy or radiotherapy in 13 patients, chemotherapy with irradiation in 2, chemotherapy alone in 2, and radiotherapy alone in 3.
  • Four were alive with disease at the time of writing and five died of disease.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Head and Neck Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10983946.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


32. Mandic R, Schamberger CJ, Müller JF, Geyer M, Zhu L, Carey TE, Grénman R, Dünne AA, Werner JA: Reduced cisplatin sensitivity of head and neck squamous cell carcinoma cell lines correlates with mutations affecting the COOH-terminal nuclear localization signal of p53. Clin Cancer Res; 2005 Oct 1;11(19 Pt 1):6845-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Head and neck squamous cell carcinomas (HNSCC) are the most frequent malignancies of the upper aerodigestive tract.
  • Cisplatin resistance is a major problem in the treatment of a large number of HNSCC cancer patients.
  • Transfection of wild-type and mutant p53 into a rat embryonic cell system showed highly reduced activity of the nuclear localization signal mutant p53 protein.
  • If these results can be validated on a larger number of tumor samples, including fresh tumor tissues, it potentially could help in sparing a subgroup of HNSCC patients the side effects associated with unnecessary chemotherapy by identifying cisplatin nonresponders before chemotherapy induction.
  • [MeSH-major] Cisplatin / pharmacology. Drug Resistance, Neoplasm. Head and Neck Neoplasms / genetics. Mutation. Nuclear Localization Signals
  • [MeSH-minor] Adult. Aged. Animals. Blotting, Western. Cell Line. Cell Line, Tumor. Cell Nucleus / metabolism. Cloning, Molecular. Coloring Agents / pharmacology. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Cytoplasm / metabolism. Dose-Response Relationship, Drug. Electrophoresis, Polyacrylamide Gel. Genes, p53 / genetics. Humans. Immunohistochemistry. Microscopy, Confocal. Middle Aged. Models, Molecular. Open Reading Frames. Protein Structure, Tertiary. Rats. Reverse Transcriptase Polymerase Chain Reaction. Tetrazolium Salts / pharmacology. Thiazoles / pharmacology. Transcription, Genetic. Transfection. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16203773.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Coloring Agents; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Nuclear Localization Signals; 0 / Tetrazolium Salts; 0 / Thiazoles; 0 / Tumor Suppressor Protein p53; 298-93-1 / thiazolyl blue; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


33. Shin DM, Khuri FR, Murphy B, Garden AS, Clayman G, Francisco M, Liu D, Glisson BS, Ginsberg L, Papadimitrakopoulou V, Myers J, Morrison W, Gillenwater A, Ang KK, Lippman SM, Goepfert H, Hong WK: Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol; 2001 Jun 15;19(12):3010-7
Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: After definitive local treatment with surgery, radiotherapy, or both, patients with locally advanced SCCHN were treated with 13-cRA (50 mg/m(2)/d, orally, daily), IFN-alpha (3 x 10(6) IU/m(2), subcutaneous injection, three times a week), and alpha-tocopherol (1,200 IU/d, orally, daily) for 12 months, with a dose modification.
  • Thirty-eight (86%) of 44 patients completed the full 12-month treatment (doses modified as needed).
  • Toxicity generally was consistent with previous IFN and 13-cRA reports and included mild to moderate mucocutaneous and flu-like symptoms; occasional significant fatigue (grade 3 in 7% of patients), mild to moderate hypertriglyceridemia in 30% of patients who continued treatment along with antilipid therapy, and mild hematologic side effects.
  • Six patients did not complete the planned treatment because of intolerable toxicity or social problems.
  • At a median 24-months of follow-up, our clinical end point rates were 9% for local/regional recurrence (four patients), 5% for local/regional recurrence and distant metastases (two patients), and 2% for SPT (one patient), which was acute promyelocytic leukemia (ie, not of the upper aerodigestive tract).
  • CONCLUSION: The novel biologic agent combination of IFN-alpha, 13-cRA, and alpha-tocopherol was generally well tolerated and promising as adjuvant therapy for locally advanced squamous cell carcinoma of the head and neck.
  • We are currently conducting a phase III randomized study of this combination (v no treatment) to confirm these phase II study results.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Drug Synergism. Female. Humans. Interferon-alpha / administration & dosage. Interferon-alpha / pharmacokinetics. Isotretinoin / administration & dosage. Isotretinoin / pharmacokinetics. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Neoplasms, Second Primary / prevention & control. Survival Analysis. Survival Rate. Vitamin E / administration & dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11408495.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA75603; United States / NCI NIH HHS / CA / CA9025
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; 1406-18-4 / Vitamin E; EH28UP18IF / Isotretinoin
  •  go-up   go-down


34. Penel N, Lefebvre D, Fournier C, Sarini J, Kara A, Lefebvre JL: Risk factors for wound infection in head and neck cancer surgery: a prospective study. Head Neck; 2001 Jun;23(6):447-55
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The goal of this prospective study is to determine risk factors for wound infections (WI) for patients with head and neck cancer who underwent surgical procedure with opening of upper aerodigestive tract mucosa.
  • Univariate analysis indicated that five variables were significantly related to the likelihood of WI: tumor stage (p =.044), previous chemotherapy (p =.008), duration of preoperative hospital stay (p = 022), permanent tracheostomy (p =.00008), and hypopharyngeal and laryngeal cancers (p =.008).
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Head and Neck Neoplasms / surgery. Surgical Wound Infection / etiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibiotic Prophylaxis. Antineoplastic Agents / adverse effects. Chemotherapy, Adjuvant / adverse effects. Female. Humans. Laryngectomy. Length of Stay. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Risk Factors. Statistics, Nonparametric. Tracheostomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 John Wiley & Sons, Inc.
  • (PMID = 11360305.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


35. Belgaumi AF, Al-Kofide A, Sabbah R, Shalaby L: Precursor B-cell lymphoblastic lymphoma (PBLL) in children: pattern of presentation and outcome. J Egypt Natl Canc Inst; 2005 Mar;17(1):15-9
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One patient had a soft tissue mass in the upper thigh while one patient had a solitary bone lesion in the distal tibia.
  • Five patients were treated according to B-cell NHL type protocols.
  • Because of the specific diagnosis of PBLL, two of these patients were switched to an ALL-type protocol following post induction intensification; one died in remission due to encephalitis, while the other remained in CR almost 2 years after diagnosis.
  • A third patient suffered a loco-regional relapse 17 months after completing first line therapy, and was re-treated on an ALL-type protocol, and currently is in remission 25 months following relapse.
  • The fourth patient, who received 9 months of post induction therapy, remains free of disease 7 years following diagnosis.
  • The fifth patient had local and CNS progression on therapy, and died of his disease.
  • The last patient with a solitary bone lesion was misdiagnosed as Ewings' Sarcoma and received treatment for that disease.
  • He suffered an isolated CNS relapse, and is in CR 12 months following the relapse, on an ALL treatment protocol.
  • CONCLUSION: PBLL is a distinct B-cell NHL which involves extralymphatic sites, with particular predisposition for the upper aerodigestive tract.
  • Patients should not be treated on short intensive protocols used for other B-cell NHL but should receive treatment based on ALL protocols like those for treating T-cell LL.
  • [MeSH-major] B-Lymphocytes / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Male. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16353078.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


36. Park SH, Gray WC, Hernandez I, Jacobs M, Ord RA, Sutharalingam M, Smith RG, Van Echo DA, Wu S, Conley BA: Phase I trial of all-trans retinoic acid in patients with treated head and neck squamous carcinoma. Clin Cancer Res; 2000 Mar;6(3):847-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although retinoids show promise for prevention of second primary upper aerodigestive tract tumors, the optimum retinoid, dose, and schedule are unknown.
  • Day 1 ATRA area under the plasma concentration versus time curve (AUC) increased with dose, and after 1-2 months of continued dosing, the AUC declined in 7 of 13 patients (54%) studied.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Tretinoin / therapeutic use
  • [MeSH-minor] Adult. Aged. Area Under Curve. Dose-Response Relationship, Drug. Exanthema / chemically induced. Female. Follow-Up Studies. Headache / chemically induced. Humans. Hypertriglyceridemia / chemically induced. Male. Middle Aged. Mouth Mucosa. Neoplasm Staging. Stomatitis / chemically induced. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10741706.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U-01-CA-69854
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin
  •  go-up   go-down


37. Keller SM, Vangel MG, Wagner H, Schiller J, Herskovic A, Komaki R, Gray R, Marks RS, Perry MC, Livingston RB, Johnson DH, Eastern Cooperative Oncology Group: Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancer. Lung Cancer; 2003 Oct;42(1):79-86
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancer.
  • The occurrence of second primary tumors (SPTs) following adjuvant therapy for resected stages II and IIIa non-small cell lung cancer (NSCLC) was investigated.
  • Data regarding SPTs were prospectively collected in all patients accrued to Eastern Cooperative Group Oncology E3590 (a phase III trial of adjuvant therapy in patients with completely resected stages II and IIIa NSCLC).
  • Thirty patients (6.1%) developed 33 SPTs, 20 in the RT arm and ten in the CRT arm.
  • Ten SPTs occurred within the upper aerodigestive tract, six in the RT arm and four in the CRT arm.
  • Median time to detection of a SPT for those patients randomized to RT and CRT was 43 and 36 months, respectively.
  • The majority of SPTs occur outside the aerodigestive tract.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / therapy. Lung Neoplasms / therapy. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Radiotherapy, Adjuvant. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14512191.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA14958; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / CA21076; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / CA21661; United States / NCI NIH HHS / CA / CA23318; United States / NCI NIH HHS / CA / CA25224; United States / NCI NIH HHS / CA / CA49957; United States / NCI NIH HHS / CA / CA66636; United States / NCI NIH HHS / CA / CA73590
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Ireland
  •  go-up   go-down


38. Cripps C, Winquist E, Devries MC, Stys-Norman D, Gilbert R, Head and Neck Cancer Disease Site Group: Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer. Curr Oncol; 2010 Jun;17(3):37-48
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
  • QUESTION: What are the benefits associated with the use of anti-epidermal growth factor receptor (anti-EGFR) therapies in squamous cell carcinoma of the head and neck (HNSCC)?
  • Anti-EGFR therapies of interest included cetuximab, gefitinib, lapatinib, zalutumumab, erlotinib, and panitumumab.
  • PERSPECTIVES: Head-and-neck cancer includes malignant tumours arising from a variety of sites in the upper aerodigestive tract.
  • The most common histologic type is squamous cell carcinoma, and most common sites are the oral cavity, the oropharynx, the hypopharynx, and the larynx.
  • Worldwide, HNSCC is the sixth most common neoplasm, and despite advances in therapy, long-term survival in HNSCC patients is poor.
  • Primary surgery followed by chemoradiation, or primary chemoradiation, are the standard treatment options for patients with locally advanced (stages III-IVB) HNSCC; however, meta-analytic data indicate that the benefit of concurrent platinum-based chemotherapy disappears in patients over the age of 70 years.
  • Cetuximab is a monoclonal antibody approved for use in combination with radiation in the treatment of patients with untreated locally advanced HNSCC and as monotherapy for patients with recurrent or metastatic (stage IVC) HNSCC who have progressed on platinum-based therapy.
  • Given the interest in anti-EGFR agents in advanced HNSCC, the Head and Neck Cancer Disease Site Group (DSG) of Cancer Care Ontario's Program in Evidence-Based Care (PEBC) chose to systematically review the literature pertaining to this topic so as to develop evidence-based recommendations for treatment.
  • OUTCOMES: Outcomes of interest included overall and progression-free survival, quality of life, tumour response rate and duration, and the toxicity associated with the use of anti-EGFR therapies.
  • The randomized controlled trials (RCTS) involved three distinct patient populations: those with locally advanced HNSCC being treated for cure, those with incurable advanced recurrent or metastatic HNSCC being treated with first-line platinum-based chemotherapy, and those with incurable advanced recurrent or metastatic HNSCC who had disease progression despite, or who were unsuitable for, first-line platinum-based chemotherapy.
  • Platinum-based chemoradiation remains the current standard of care for treatment of locally advanced HNSCC.
  • In patients with locally advanced HNSCC who are medically unsuitable for concurrent platinum based chemotherapy or who are over the age of 70 years (because concurrent chemotherapy does not appear to improve overall survival in this patient population), the addition of cetuximab to radical radiotherapy should be considered to improve overall survival, progression-free survival, and time to local recurrence.Cetuximab in combination with platinum-based combination chemotherapy is superior to chemotherapy alone in patients with recurrent or metastatic HNSCC, and is recommended to improve overall survival, progression-free survival, and response rate.The role of anti-EGFR therapies in the treatment of locally advanced HNSCC is currently under study in large randomized trials, and patients with HNSCC should continue to be offered clinical trials of novel agents aimed at improving outcomes.
  • However, five ongoing trials are investigating the effect of the addition of EGFR inhibitors concurrently with, before, or after chemoradiotherapy; those trials should provide direction about the best integration of cetuximab into standard treatment.
  • In patients with recurrent or metastatic HNSCC who experience progressive disease despite, or who are unsuitable for, first-line platinum-based chemotherapy, gefitinib at doses of 250 mg or 500 mg daily, compared with weekly methotrexate, did not increase median overall survival [hazard ratio (hr): 1.22; 96% confidence interval (ci): 0.95 to 1.57; p = 0.12 (for 250 mg daily vs. weekly methotrexate); hr: 1.12; 95% ci: 0.87 to 1.43; p = 0.39 (for 500 mg daily vs. weekly methotrexate)] or objective response rate (2.7% for 250 mg and 7.6% for 500 mg daily vs. 3.9% for weekly methotrexate, p > 0.05).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1995 Jul;72(1):123-8 [7599040.001]
  • [Cites] N Engl J Med. 2008 Oct 23;359(17):1757-65 [18946061.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):1226-31 [9508211.001]
  • [Cites] Eur J Cancer. 2000 Sep;36(14):1796-807 [10974628.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1523-32 [11410486.001]
  • [Cites] Semin Oncol. 2002 Oct;29(5 Suppl 14):18-30 [12422310.001]
  • [Cites] Cancer Res. 2003 Feb 1;63(3):555-9 [12566295.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):246-54 [12909240.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):341-54 [15864276.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 6:vi20-vi24 [15987992.001]
  • [Cites] Expert Opin Biol Ther. 2005 Aug;5(8):1085-93 [16050785.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8646-54 [16314626.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2659-65 [16763280.001]
  • [Cites] Cancer Biol Ther. 2006 Apr;5(4):340-2 [16808060.001]
  • [Cites] J Dent Res. 2007 Feb;86(2):104-14 [17251508.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2191-7 [17538164.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S112-4 [17848275.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1626-34 [18316791.001]
  • [Cites] J Natl Cancer Inst. 2008 Mar 19;100(6):407-20 [18334711.001]
  • [Cites] N Engl J Med. 2008 Sep 11;359(11):1116-27 [18784101.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):502-12 [7844612.001]
  • (PMID = 20567625.001).
  • [ISSN] 1718-7729
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2880902
  • [Keywords] NOTNLM ; Head-and-neck cancer / egfr inhibitors / epidermal growth factor receptor / overall survival / progression-free survival / tumour response rate
  •  go-up   go-down


39. Terrell JE, Ronis DL, Fowler KE, Bradford CR, Chepeha DB, Prince ME, Teknos TN, Wolf GT, Duffy SA: Clinical predictors of quality of life in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg; 2004 Apr;130(4):401-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN, PATIENTS, AND SETTING: A convenience sample of 570 patients with upper aerodigestive tract cancers were surveyed at a tertiary care oncology clinic and Veterans Affairs otolaryngology clinic.
  • Tumor site and tumor stage, clinical, and treatment data were abstracted from the patient medical records.
  • In descending order of severity, medical comorbid conditions, presence of a tracheotomy tube, chemotherapy, and neck dissection were also associated with significant (P<.05) decrements in QoL domains.
  • [MeSH-major] Otorhinolaryngologic Neoplasms / psychology. Quality of Life / psychology. Sick Role
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Alcohol Drinking / adverse effects. Alcohol Drinking / psychology. Chemotherapy, Adjuvant / psychology. Combined Modality Therapy / psychology. Comorbidity. Depression / diagnosis. Depression / psychology. Enteral Nutrition / psychology. Female. Follow-Up Studies. Health Behavior. Health Status Indicators. Humans. Laryngectomy / psychology. Male. Middle Aged. Neck Dissection / psychology. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant / psychology. Sickness Impact Profile. Smoking / adverse effects. Smoking / psychology. Tracheotomy / psychology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15096421.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 P50 CA97248
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


40. Harb WJ, Luna MA, Patel SR, Ballo MT, Roberts DB, Sturgis EM: Survival in patients with synovial sarcoma of the head and neck: association with tumor location, size, and extension. Head Neck; 2007 Aug;29(8):731-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thus, we determined whether clinical characteristics and treatment were associated with recurrence and survival rates in patients with SS of the head and neck.
  • METHODS: We retrospectively identified patients with a pathologic diagnosis of SS of the head and neck at our institution (a large tertiary comprehensive cancer center) and compared recurrence and survival rates by clinical characteristics and treatment.
  • RESULTS: Forty patients with SS of the head and neck were identified from 1945 to 2004 (first case in 1968), representing <5% of all head and neck sarcomas seen at our institution during this time period.
  • Most patients were male (73%), with a median age of 29 years.
  • Higher disease-specific and overall survival rates were associated with upper aerodigestive tract location, tumors of < or =5 cm, and tumors did not extend into bone.
  • Patients treated with surgery and adjuvant radiotherapy had higher survival and lower recurrence rates than did those treated with surgery alone or a combination of surgery, radiotherapy, and chemotherapy.
  • CONCLUSIONS: SS of the head and neck is extremely rare, and our results should be viewed with caution given the relatively small group size and treatment over a 36-year period.
  • Treatment of SS of the head and neck should be directed toward complete surgical resection.
  • Given the known sensitivity of SS to contemporary chemotherapy, a multimodality approach should be considered in the perioperative setting, especially in high risk patients.
  • [MeSH-major] Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / surgery. Neoplasm Recurrence, Local / epidemiology. Sarcoma, Synovial / mortality. Sarcoma, Synovial / surgery
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Linear Models. Male. Medical Records. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Texas / epidemiology. Treatment Outcome

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17274049.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement